LTR Pharma Limited (ASX:LTP)

Australia · Delayed Price · Currency is AUD

0.5200

+0.0200 (4.00%)

At close: Jul 10, 2026

79.31% (1Y)

Market Cap	94.52M +74.1%
Revenue (ttm)	1.13M +126.4%
Net Income	-8.95M
EPS	-0.05
Shares Out	181.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,606
Open	0.5000
Previous Close	0.5000
Day's Range	0.5000 - 0.5200
52-Week Range	0.2820 - 0.8100
Beta	2.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2020

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol LTP

Full Company Profile

Financial Performance

In fiscal year 2025, LTR Pharma's revenue was 1.51 million, an increase of 2978.25% compared to the previous year's 49,002. Losses were -5.59 million, -19.57% less than in 2024.

Financial Statements